Latest UCB News & Updates

See the latest news and media coverage for UCB. We track all announcements, press releases, and industry mentions in real time, all in one place.

UCB

Global biopharmaceutical company for neurological and immune‑mediated diseases

ucb.com

Headquarters: Brussels, Belgium
Founded year: 1928
Company type: Private company
Number of employees: 5,000–20,000
Industry: Pharmaceuticals

Last updated Today

Latest news about UCB

In short: UCB expanded its portfolio through the $2.2 billion acquisition of Candid Therapeutics and the $1.15 billion purchase of Neurona Therapeutics.

Company announcements

July 30 UCB

UCB reported strong half year results for 2026

Total revenue grew 27% to €4.27 billion, with pipeline progress and acquisitions expanding innovation capabilities.

July 30 UCB

UCB reports strong H1 2026 financial results

Total revenue grew 22% to €4.27 billion and adjusted EBITDA rose 68% to €1.74 billion, with updated full-year guidance.

June 17 UCB

UCB completes acquisition of Candid Therapeutics

The $2.2B deal adds cizutamig, a BCMA T-cell engager, to UCB's immunology pipeline.

June 2 UCB

UCB completes acquisition of Neurona Therapeutics

The deal adds Neurona's cell therapy pipeline and entrepreneurial team to UCB's neuroscience portfolio.

Media coverage

July 31 Investing.com

Earnings Call Summary: UCB Raises 2026 Outlook, BIMZELX First-Half Sales Doubled

Management stated that, supported by product mix optimization, the full-year gross margin is still expected to further improve compared to 2025. Management Commentary CEO Jean-Christophe Tellier said the company's growth foundation is continuously broadening. He said: "Our five growth-driver products have contributed over 50% of revenue," and added that the product portfolio "achieved net sales growth of over 28% on a constant currency basis." Tellier also emphasized the clinical value of BIMZELX. He said that the drug is the first to demonstrate superiority over biologics in psoriatic arthritis...

July 30 Investing.com

UCB raises 2026 outlook as BIMZELX sales double in H1

Risk warning: Trading in financial instruments and/or cryptocurrencies involves a high risk, such as the chance that you lose all or part of the...

July 30 Testaankoop

UCB falls despite strong results: Bimzelx causes concern

Heavy blow for the biopharmaceutical group UCB, whose shares lost more than 10% on 30/7. However, the half-year results were well in line with expectations, with a...

July 30 Yahoo Finance

UCB SA (UCBJF) (H1 2026) Earnings Call Highlights: Record Sales and Strategic Expansion Drive ...

Total Net Sales: Grew 23% to EUR4.1 billion in H1 2026. Total Revenue: Increased 22% (27% at constant rate) to EUR4.3 billion. Adjusted Gross Profit...

Never miss news about UCB

Track UCB and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

UCB competitors & trending companies

Browse news for competitors to UCB and other trending companies.